Cagrilintide
ALSO KNOWN AS · AM833
A long-acting amylin analogue, developed both alone and combined with semaglutide as CagriSema. Amylin acts on a satiety pathway distinct from the incretin axis.
Mechanism
Amylin is co-secreted with insulin by beta cells and signals satiety through the area postrema. Because the pathway differs from GLP-1, combining the two produces additive appetite suppression rather than overlapping effects.
Clinical evidence
REDEFINE-1 reported mean weight reduction of about 22.7% at 68 weeks for CagriSema in adults with obesity and without diabetes.
PRIMARY SOURCES
- 01CagriSema REDEFINE-1— New England Journal of Medicine
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.